The Perils of Purchase-Order Contracting In Pharmaceutical Transactions - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Perils of Purchase-Order Contracting In Pharmaceutical Transactions
Purchase-order contracting is a commonly used approach to conducting commercial transactions, but it is a risky proposition when applied to pharmaceutical transactions, including the buying and selling of contract services and pharmaceutical ingredients. The authors examine the contract provisions covered in a commercial-supply agreement that are likely to be omitted under purchase-order contracting and the risk-reduction benefits that a commercial-supply agreement can offer in pharmaceutical procurement.

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 3, Issue 9

Looking forward

Failing to contractually address well-known "hot-button" issues, and hoping (essentially holding your breath) that contractual disputes will not arise and litigation will be unnecessary is a recipe for disaster. Suppliers and purchasers are well advised to negotiate commercial-supply agreements in advance of problems, spelling out the parties respective rights and obligations. Because of the substantial financial and legal risks, purchase-order contracting in pharmaceutical transactions should generally be avoided.

Stephen D. Sayre is a member of Dykema's corporate finance department and Todd Grant Gattoni* is a member of Dykema with his practice concentrated on products liability, business, and chemical exposure toxic-tort litigation, including pharmaceutical and medical device manufacturers in mass tort and class-action lawsuits involving commercial-supply agreements, 400 Renaissance Center, Detroit, MI 48243, tel. 313.568.5318, fax 313.568.6893,

* To whom correspondence should be directed.


1. FDA, The Center for Drug Evaluation and Research's Report to the Nation: 2005 (FDA, Rockville, MD, 2005), http://, accessed Aug. 27, 2007.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here